Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune checkpoint inhibitors

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune checkpoint inhibitors

Background: There is a lack of real-world data on the use of cabozantinib in Asian patients with metastatic renal cell carcinoma. Methods: We conducted a retrospective study to investigate the toxicity and efficacy of cabozantinib in this patient population who progressed on tyrosine kinase inhib...

Full description

Bibliographic Details
Main Authors: Darren MC Poon, Kuen Chan, Angus Kwong-Chuen Leung, Brian Ng, Foon-Yiu Cheung, Steven Wai-Kwan Siu, Hong Kong Society of Uro-Oncology
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2023-06-01
Series:Drugs in Context
Subjects:
immuno-oncology
metastatic renal cell carcinoma
real-world effectiveness
sequential therapies
targeted therapy
tyrosine kinase inhibitors
vascular endothelial growth factor receptor
Online Access:https://www.drugsincontext.com/real-world-experience-of-cabozantinib-in-asian-patients-with-advanced-renal-cell-carcinoma-following-treatment-with-vegfr-tyrosine-kinase-inhibitors-and-or-immune-checkpoint-inhibitors

Internet

https://www.drugsincontext.com/real-world-experience-of-cabozantinib-in-asian-patients-with-advanced-renal-cell-carcinoma-following-treatment-with-vegfr-tyrosine-kinase-inhibitors-and-or-immune-checkpoint-inhibitors

Similar Items